Peter Radovich currently serves as president and chief operating officer at Mirum where he is responsible for commercial, corporate development, chemistry, manufacturing and controls (CMC), and supply chain. Peter joined Mirum in April 2020 as chief operating officer with more than 20 years of operational experience in the biopharmaceutical industry.
Prior to Mirum, he served as executive vice president, operations at Global Blood Therapeutics (GBT) from 2014 to 2020, responsible for technical operations, supply chain, program management and leadership, quality assurance, and commercial strategy and analytics functions. From 2006 to 2014, Peter worked at Onyx Pharmaceuticals, Inc. (now Amgen, Inc.) serving in a variety of roles including vice president, program leadership, as well as commercial and corporate strategy roles. Prior to Onyx, Peter held product marketing positions at Chiron Corporation (now Novartis AG).
Peter is also a board member at Rain Therapeutics Inc., a precision oncology company. Peter received an M.B.A. from Washington University in St. Louis and his undergraduate degree in biology and chemistry from Texas Christian University.
What is Peter Radovich's net worth?
The estimated net worth of Peter Radovich is at least $1.34 million as of March 17th, 2025. Mr. Radovich owns 18,672 shares of Mirum Pharmaceuticals stock worth more than $1,335,608 as of December 5th. This net worth approximation does not reflect any other assets that Mr. Radovich may own. Additionally, Mr. Radovich receives an annual salary of $881,800.00 as President & Chief Operating Officer at Mirum Pharmaceuticals. Learn More about Peter Radovich's net worth.
How old is Peter Radovich?
Mr. Radovich is currently 46 years old. There are 5 older executives and no younger executives at Mirum Pharmaceuticals. The oldest executive at Mirum Pharmaceuticals is Mr. Eric H. Bjerkholt M.B.A., Chief Financial Officer, who is 64 years old. Learn More on Peter Radovich's age.
What is Peter Radovich's salary?
As the President & Chief Operating Officer of Mirum Pharmaceuticals, Inc., Mr. Radovich earns $881,800.00 per year. The highest earning executive at Mirum Pharmaceuticals is Mr. Christopher Peetz, Co-Founder, CEO and Director, who commands a salary of $1,310,000.00 per year. Learn More on Peter Radovich's salary.
How do I contact Peter Radovich?
Has Peter Radovich been buying or selling shares of Mirum Pharmaceuticals?
Peter Radovich has not been actively trading shares of Mirum Pharmaceuticals in the last ninety days. Most recently, Peter Radovich sold 7,879 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.21, for a transaction totalling $348,330.59. Following the completion of the sale, the chief operating officer now directly owns 18,672 shares of the company's stock, valued at $825,489.12. Learn More on Peter Radovich's trading history.
Who are Mirum Pharmaceuticals' active insiders?
Mirum Pharmaceuticals' insider roster includes Eric Bjerkholt (CFO), Laura Brege (Director), Ian Clements (CFO), James Flynn (Major Shareholder), Michael Grey (Chairman of the Board), Patrick Heron (Director), Jolanda Howe (SVP), Lara Longpre (Chief Development Officer), Christopher Peetz (Co-Founder, CEO and Director), Joanne Quan (Chief Medical Officer), Peter Radovich (President & Chief Operating Officer), Saira Ramasastry (Director), and Pamela Vig (Insider). Learn More on Mirum Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Mirum Pharmaceuticals?
During the last twelve months, Mirum Pharmaceuticals insiders bought shares 1 times. They purchased a total of 1,335 shares worth more than $60,835.95. During the last twelve months, insiders at the sold shares 20 times. They sold a total of 251,298 shares worth more than $13,320,529.08. The most recent insider tranaction occured on September, 12th when CFO Eric Bjerkholt sold 9,578 shares worth more than $728,023.78. Insiders at Mirum Pharmaceuticals own 14.4% of the company.
Learn More about insider trades at Mirum Pharmaceuticals. Information on this page was last updated on 9/12/2025.
